Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14690329 | 1.00 | MLYCD (0.48) | MLYCDALDH1A1GLATSHR | |
| SCHEMBL10487589 | 0.87 | MLYCD (0.49) | MLYCD | |
| SCHEMBL28110901 | 0.87 | MLYCD (0.46) | MLYCDALDH1A1GLATSHR | |
| SCHEMBL10487587 | 0.87 | MLYCD (0.49) | MLYCD | |
| SCHEMBL10333122 | 0.87 | ALDH1A1 (0.43) | ALDH1A1GLATSHR | |
| SCHEMBL10425651 | 0.87 | ALDH1A1 (0.43) | ALDH1A1GLATSHR | |
| SCHEMBL9716707 | 0.86 | MLYCD (0.61) | MLYCDALDH1A1GLATSHR | |
| SCHEMBL5493790 | 0.85 | MLYCD (0.45) | MLYCDALDH1A1GLATSHR | |
| SCHEMBL10951512 | 0.84 | ALDH1A1 (0.61) | MLYCDALDH1A1GLATSHR | |
| SCHEMBL5967205 | 0.84 | MLYCD (0.50) | MLYCDALDH1A1GLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092608-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | TANABE SEIYAKU CO., LTD. (JP) | 2003-05-15 | — | — | US | claimed |
| US-5892043-A | MIXTURE WITH POLYSACCHARIDE AND PEPTIDE; ANTITUMOR AGENT | TANABE SEIYAKU CO., LTD. (JP) | 1999-04-06 | — | — | US | claimed |
| EP-0757049-B1 | Camptothecin derivatives | TANABE SEIYAKU CO (JP) | 1999-03-24 | — | — | EP | claimed |
| US-20130039930-A1 | BIOMARKER FOR SENSITIVITY TO THERAPY WITH A NOTCH INHIBITOR | VEGENICS PTY LIMITED (AU) | 2013-02-14 | — | — | US | disclosed |
| US-20060052288-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20030092608-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | TANABE SEIYAKU CO., LTD. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| US-4736066-A | Intermediate for substituted peptide compounds | E. R. SQUIBB & SONS, INC. (US) | 1988-04-05 | — | — | US | disclosed |
| EP-0071544-B1 | PHOSPHONAMIDATE COMPOUNDS | E.R. Squibb & Sons, Inc. (US) | 1986-10-08 | — | — | EP | disclosed |
| US-4535176-A | HYPOTENSIVE AGENTS, ANALGESICS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1985-08-13 | — | — | US | disclosed |
| US-4470973-A | HYPOTENSIVE AGENTS, ANALGESICS | E. R. SQUIBB & SONS, INC. (US) | 1984-09-11 | — | — | US | disclosed |
| US-4432971-A | HYPOTENSIVE AGENTS AND ANGIOTENSIN INHIBITION | E. R. SQUIBB & SONS, INC. (US) | 1984-02-21 | — | — | US | disclosed |
| US-4432972-A | HYPOTENSIVE AGENTS, KANALGESICS, AND ANGIOTENSIN AND ENKEPHALIN INHIBITION | E. R. SQUIBB & SONS, INC. (US) | 1984-02-21 | — | — | US | disclosed |
| EP-0071544-A1 | Phosphonamidate compounds | E.R. Squibb & Sons, Inc. (US) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092608-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | CD44, MUC1, HGFAC | MLYCD 4005/4885ALDH1A1 4169/4885GLA 2345/4885 |
| US-20060052288-A1 | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor | CD44, MUC1, HGFAC | MLYCD 4005/4885ALDH1A1 4169/4885GLA 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.